The Protocol Review Committee (PRC) of University of Pittsburgh Cancer Institute (UPCI) is responsible for reviewing all clinical cancer research studies conducted at the University of Pittsburgh and UPMC prior to initiation of the study. Its activities are overseen by the Clinical Research Oversight Committee (CROC) along with two other entities that work in parallel to orchestrate cancer clinical research, the Data Safety and Monitoring Committee (DSMC) and the Clinical Research Services (CRS). The PRC also works in conjunction with three other parts of the clinical trials enterprise, the University of Pittsburgh IRB, the UPCI Biostatistics Facility, and the disease-oriented management teams, to promote the highest scientific quality and most efficient conduct of cancer clinical trials at the UPCI. The PRC is comprised of three committees. Committees A and B each meet once a month in order to facilitate prompt review of cancer treatment protocols. Committee C is responsible for reviewing all behavioral, cancer epidemiology, cancer prevention and control, and complementary medicine protocols as the need arises. The PRC evaluates each protocol to ensure appropriate study design and scientific quality and availability of patient and fiscal resources required for successful completion of the trial proposed. Membership of the PRC includes a diverse group of cancer experts including hematology/oncology, surgical oncology, urologic oncology, pharmacology, biostatistics, nursing, regulatory affairs, and laboratory scientists. PRC approval of cancer clinical trials is required before the study can be submitted to the University of Pittsburgh IRB. All UPCI trials are reviewed for accrual every six months. Studies achieving less than 30% of target accrual are flagged for review. A notification letter is sent to the PI requesting a plan to increase accrual, and the study is re-reviewed for accrual in six months. To simplify documentation and monitoring of UPCI clinical trials activities, all formal committees (PRC, CROC and three DSMC) have a single recording secretary, who is responsible for recording the minutes of each meeting, and facilitates communication between the committees, University and UPMC regulatory committees, regulatory agencies, and UPCI PIs.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA047904-26
Application #
8705423
Study Section
Special Emphasis Panel (ZCA1-RTRB-L)
Project Start
Project End
Budget Start
2014-08-01
Budget End
2015-07-31
Support Year
26
Fiscal Year
2014
Total Cost
$62,881
Indirect Cost
$21,283
Name
University of Pittsburgh
Department
Type
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Chen, Dongshi; Ni, Hong-Min; Wang, Lei et al. (2018) PUMA induction mediates acetaminophen-induced necrosis and liver injury. Hepatology :
Tahata, Shawn; Singh, Shivendra V; Lin, Yan et al. (2018) Evaluation of Biodistribution of Sulforaphane after Administration of Oral Broccoli Sprout Extract in Melanoma Patients with Multiple Atypical Nevi. Cancer Prev Res (Phila) 11:429-438
Moravcikova, Erika; Meyer, E Michael; Corselli, Mirko et al. (2018) Proteomic Profiling of Native Unpassaged and Culture-Expanded Mesenchymal Stromal Cells (MSC). Cytometry A 93:894-904
Samuelsson, Laura B; Bovbjerg, Dana H; Roecklein, Kathryn A et al. (2018) Sleep and circadian disruption and incident breast cancer risk: An evidence-based and theoretical review. Neurosci Biobehav Rev 84:35-48
Shiffman, Saul; Mao, Jason M; Kurland, Brenda F et al. (2018) Do non-daily smokers compensate for reduced cigarette consumption when smoking very-low-nicotine-content cigarettes? Psychopharmacology (Berl) 235:3435-3441
Cao, Chunyu; Wu, Hao; Vasilatos, Shauna N et al. (2018) HDAC5-LSD1 axis regulates antineoplastic effect of natural HDAC inhibitor sulforaphane in human breast cancer cells. Int J Cancer 143:1388-1401
Yochum, Zachary A; Cades, Jessica; Wang, Hailun et al. (2018) Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer. Oncogene :
Beumer, Jan H; Inker, Lesley A; Levey, Andrew S (2018) Improving Carboplatin Dosing Based on EstimatedĀ GFR. Am J Kidney Dis 71:163-165
Tong, Jingshan; Zheng, Xingnan; Tan, Xiao et al. (2018) Mcl-1 Phosphorylation without Degradation Mediates Sensitivity to HDAC Inhibitors by Liberating BH3-Only Proteins. Cancer Res 78:4704-4715
Menk, Ashley V; Scharping, Nicole E; Rivadeneira, Dayana B et al. (2018) 4-1BB costimulation induces T cell mitochondrial function and biogenesis enabling cancer immunotherapeutic responses. J Exp Med 215:1091-1100

Showing the most recent 10 out of 1187 publications